|
PAFAH1B1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.3028245976775E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.00619529269852E-11 |
| Normal-vs-Stage2 |
4.383300E-04 |
| Normal-vs-Stage3 |
4.12010425776543E-11 |
| Normal-vs-Stage4 |
1.84741111297626E-12 |
| Stage1-vs-Stage2 |
8.154300E-02 |
| Stage1-vs-Stage3 |
3.603800E-01 |
| Stage1-vs-Stage4 |
3.315000E-03 |
| Stage2-vs-Stage3 |
2.948300E-02 |
| Stage2-vs-Stage4 |
8.643000E-04 |
| Stage3-vs-Stage4 |
7.989800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.0547118733939E-13 |
| Normal-vs-AfricanAmerican |
1.781930E-04 |
| Normal-vs-Asian |
2.84500000002907E-07 |
| Caucasian-vs-AfricanAmerican |
3.479000E-01 |
| Caucasian-vs-Asian |
7.404800E-01 |
| AfricanAmerican-vs-Asian |
5.700400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.70767910501991E-12 |
| Normal-vs-Female |
1.33449917782968E-11 |
| Male-vs-Female |
4.854800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.99780003440742E-10 |
| Normal-vs-Age(41-60Yrs) |
5.00830488192605E-11 |
| Normal-vs-Age(61-80Yrs) |
2.19860019079476E-10 |
| Normal-vs-Age(81-100Yrs) |
2.764100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.016000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.548200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.772800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.786000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.511400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.648200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.284100E-03 |
| Classical-VS-Follicular |
9.204400E-01 |
| Classical-VS-Other |
6.823900E-02 |
| Classical-VS-Normal |
4.09140499257887E-11 |
| Tall-VS-Follicular |
1.560200E-02 |
| Tall-VS-Other |
6.039200E-01 |
| Tall-VS-Normal |
2.62279975515867E-10 |
| Follicular-VS-Other |
1.448440E-01 |
| Follicular-VS-Normal |
4.56350000010985E-07 |
| Other-VS-Normal |
5.67040000000185E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.18300003126848E-09 |
| Normal-vs-N1 |
7.08533232085529E-12 |
| N0-vs-N1 |
1.124270E-02 |
|
|
